Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | WINDLAS Windlas Biotech Limited Pharma · Small | BETA Beta Drugs Limited Pharma · Small | JAGSNPHARM Jagsonpal Pharmaceuticals Limited Pharma · Small | WANBURY Wanbury Limited Pharma · Small |
|---|---|---|---|---|
| Final Score | 45 | 47 | 57 | 64 |
| Verdict | WATCHLIST | FAIR VALUE | FAIR VALUE | UNDERVALUED |
| Style | Financial Turnaround | Financial Turnaround | Financial Turnaround | Growth at Value |
| Piotroski | 8/9 | 8/9 | 8/9 | 7/9 |
| Valuation | 10/30 | 4/30 | 7/30 | 16/30 |
| Growth | 12/25 | 16/25 | 16/25 | 21/25 |
| Quality | 2/20 | 10/20 | 12/20 | 18/20 |
| Balance Sheet | 12/15 | 8/15 | 12/15 | 0/15 |
| Cash Flow | 4/10 | 4/10 | 5/10 | 4/10 |
| Price | ₹835.4 | ₹1,522.9 | ₹201.75 | ₹265.75 |
| P/E | 26.00 | 37.20 | 29.30 | 13.30 |
| P/B | 3.04 | 6.32 | 4.83 | 6.44 |
| ROE | 12.20% | 18.80% | 17.30% | 68.40% |
| ROCE | 15.90% | 19.20% | 22.70% | 30.80% |
| Debt / Equity | 0.06 | 0.60 | 0.03 | 1.54 |
| FCF Yield | 0.75% | — | 0.84% | — |
| Dividend Y | 0.69% | — | 1.26% | — |
| Altman Z | 5.67 | 5.81 | 8.98 | 3.83 |
| Promoter % | 63.31% | 64.63% | 67.89% | 43.01% |
| Mkt Cap (₹Cr) | 1728.00 | 1544.00 | 1308.00 | 928.00 |
| Graham # | ₹441.41 | ₹471.05 | ₹77.2 | ₹132.63 |
| Fair PE | 42.0 | 42.0 | 42.0 | 42.0 |
| MoS % | +36.8% | +11.4% | +25.3% | +66.6% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startWINDLAS77
BETA91
JAGSNPHARM34
WANBURY102